The ErbB3-targeting antibody MM-121 (seribantumab) reverses heregulin-driven resistance to multiple chemotherapies on tumor cell growth

被引：0
|
作者：
Masson, Kristina [1 ]
Grantcharova, Viara [1 ]
Burenkova, Olga [1 ]
Wainszelbaum, Marisa [1 ]
Iadevaia, Sergio [1 ]
Adams, Sharlene [1 ]
Raue, Andreas [1 ]
Czibere, Akos [1 ]
Schoeberl, Birgit [1 ]
MacBeath, Gavin [1 ]
机构：
[1] Merrimack Pharmaceut, Cambridge, MA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-LB-243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-243
引用
收藏
页数：3
相关论文
共 10 条
  • [1] Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
    Schoeberl, Birgit
    Kudla, Art
    Masson, Kristina
    Kalra, Ashish
    Curley, Michael
    Finn, Gregory
    Pace, Emily
    Harms, Brian
    Kim, Jaeyeon
    Kearns, Jeff
    Fulgham, Aaron
    Burenkova, Olga
    Grantcharova, Viara
    Yarar, Defne
    Paragas, Violette
    Fitzgerald, Jonathan
    Wainszelbaum, Marisa
    West, Kip
    Mathews, Sara
    Nering, Rachel
    Adiwijaya, Bambang
    Garcia, Gabriela
    Kubasek, Bill
    Moyo, Victor
    Czibere, Akos
    Nielsen, Ulrik B.
    MacBeath, Gavin
    NPJ SYSTEMS BIOLOGY AND APPLICATIONS, 2017, 3
  • [2] Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
    Birgit Schoeberl
    Art Kudla
    Kristina Masson
    Ashish Kalra
    Michael Curley
    Gregory Finn
    Emily Pace
    Brian Harms
    Jaeyeon Kim
    Jeff Kearns
    Aaron Fulgham
    Olga Burenkova
    Viara Grantcharova
    Defne Yarar
    Violette Paragas
    Jonathan Fitzgerald
    Marisa Wainszelbaum
    Kip West
    Sara Mathews
    Rachel Nering
    Bambang Adiwijaya
    Gabriela Garcia
    Bill Kubasek
    Victor Moyo
    Akos Czibere
    Ulrik B Nielsen
    Gavin MacBeath
    npj Systems Biology and Applications, 3
  • [3] A phase I study of MM-121 (a fully human monoclonal antibody targeting the epidermal growth factor receptor family member ErbB3) in combination with cetuximah and irinotecan in patients with advanced cancers
    Cleary, James M.
    McRee, Autumn Jackson
    O'Nei, Bert H.
    Sharma, Sunil
    Pearlberg, Joseph
    Manoli, Sara
    Kubasek, William Lloyd
    Korn, W. Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] MM-121 (SAR256212), an Anti-ErbB3 Monoclonal Antibody, Shows Synergistic Tumor Growth Inhibition in Combination with a Pan-PI3K Inhibitor or a Microtubule Inhibitor Through ErbB3 Expression Modulation
    Henry, C.
    Geslin, C.
    Blanchet, A. M.
    Nicolazzi, C.
    Garcia, G.
    Vincent, L.
    Blanc, V.
    Tabah-Fisch, I.
    Chiron, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 99 - 99
  • [5] Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
    Jiang, Ning
    Wang, Dongsheng
    Hu, Zhongliang
    Shin, Hyung Ju C.
    Qian, Guoqing
    Rahman, Mohammad Aminur
    Zhang, Hongzheng
    Amin, A. R. M. Ruhul
    Nannapaneni, Sreenivas
    Wang, Xiaojing
    Chen, Zhengjia
    Garcia, Gabriela
    MacBeath, Gavin
    Shin, Dong M.
    Khuri, Fadlo R.
    Ma, Jun
    Chen, Zhuo G.
    Saba, Nabil F.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (07) : 1826 - 1836
  • [6] MM-121/SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER plus breast cancer model.
    Curley, Michael D.
    Sabnis, Gauri
    Wille, Lucia
    Garcia, Gabriela
    Moyo, Victor
    Kazi, Armina
    MacBeath, Gavin
    Brodie, Angela
    CANCER RESEARCH, 2013, 73 (08)
  • [7] A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.
    Sequist, Lecia V.
    Lopez-Chavez, Ariel
    Doebele, Robert Charles
    Gray, Jhanelle Elaine
    Harb, Wael A.
    Modiano, Manuel R.
    Jackman, David Michael
    Baggstrom, Maria Quintos
    Atmaca, Akin
    Felip, Enriqueta
    Provencio, Mariano
    Cobo, Manuel
    Kripas, Christopher J.
    MacBeath, Gavin
    Czibere, Akos Gabor
    Cho, Byoung Chul
    Park, Keunchil
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] ISU104, a fully human antibody targeting a specific epitope on the ErbB3, displays potent inhibition of tumor growth in multiple xenograft tumor models
    Kim, Miyoung
    Hur, Youngmi
    Seo, Sohyeon
    Lim, Heynjeong
    Kim, Kyungyong
    Sohn, Youngsoo
    Hong, Seung-Beom
    Bae, Donggoo
    CANCER RESEARCH, 2018, 78 (13)
  • [9] A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.
    Liu, Joyce
    Ray-Coquard, Isabelle Laure
    Selle, Frederic
    Poveda, Andres
    Cibula, David
    Hirte, Hal W.
    Raspagliesi, Francesco
    Gladieff, Laurence
    Harter, Philipp
    Schiavetto, Ilaria
    Tabah-Fisch, Isabelle Marie
    MacBeath, Gavin
    Czibere, Akos Gabor
    Naumann, R. Wendel
    Coleman, Robert L.
    Vergote, Ignace
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer
    Higgins, Michaela Jane
    Doyle, Catherine
    Paepke, Stefan
    Azaro, Analia
    Martin, Miguel
    Semiglazov, Vladimir
    Smirnova, Iya
    Krasnozhon, Dmitriy
    Manikhas, Alexey
    Harb, Wael A.
    Panasci, Lawrence C.
    Pearlberg, Joseph
    MacBeath, Gavin
    Nering, Rachel
    Goss, Paul E.
    Miller, Kathy
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
1